2EB0 Stock Chart & Stats
€3.36
€0.04(1.20%)
At close: 4:00 PM EDT
€3.36
€0.04(1.20%)
Day’s Range― - ―
52-Week Range€2.80 - €25.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.59M
Enterprise Value-€1.08
Total Cash (Recent Filing)€10.80M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Nov 05, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.12
Shares Outstanding2,008,418
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.98Price Target Upside435.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-5.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
QRX003 Has A Differentiated Rare-disease OpportunityQRX003 addresses a severe disease with limited treatment options and could become the first approved Netherton Syndrome therapy. This unmet need may support regulatory attention, patient adoption and durable commercial differentiation if clinical development succeeds.
Broad Orphan-drug And Expedited Regulatory SupportMultiple regulatory designations can reduce development friction and improve access to agency guidance, incentives and potential exclusivity. The international profile also supports a broader commercialization strategy for the lead program.
Debt-free Balance Sheet Limits Leverage RiskThe absence of reported debt protects the company from interest obligations, refinancing pressure and lender restrictions while its pipeline remains in development. This provides some financial flexibility, although it does not remove the need for future funding.
Bears Say
No Revenue And Materially Widening LossesQuoin has not yet demonstrated commercial revenue generation, and recent losses are expanding as development spending continues. The absence of operating income leaves fundamentals dependent on successful clinical progress and eventual regulatory approval.
Accelerating Cash Burn Increases Funding RiskA sharp increase in cash outflows reduces the runway available to fund trials, regulatory work and operations. Without revenue or positive operating cash flow, Quoin may need additional capital before commercialization, creating execution and dilution risk.
Shrinking Equity And Asset Base Signals Value ErosionDeclining equity and assets indicate that ongoing losses are consuming the company’s financial base despite its lack of debt. This weakens resilience during clinical development and may constrain strategic options if funding conditions become difficult.
Quoin Pharmaceuticals News
2EB0 FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was €2.80 and its highest was €25.00 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is €9.59M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€1.625 earnings per share for the quarter, missing the consensus estimate of -€1.377 by -€0.248.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -1.31.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 2,008,418 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -€1.625 in its last earnings report, missing expectations of -€1.377. Following the earnings report the stock price went up 6.092%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2EB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
2EB0 Stock 12 Month Forecast
Average Price Target
€17.98
▲(435.04% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―